Alzheimer’s Disease (AD) is a neurodegenerative disorder that targets the brain and disrupts vital processes of neural networks causing the decline of cognitive function. The main pathological mechanisms responsible for the development of Alzheimer’s are the tau and amyloid-beta proteins. These proteins are detrimental because they form plaque and neurofibrillary tangles that aggregate within the brain. Biomarkers and diagnostic tools are utilized to detect Alzheimer’s within a patient. These devices can potentially detect the onset of Alzheimer’s early, reducing the severity of symptoms. Throughout studies of various research articles, certain potential AD treatments were analyzed to determine their efficacy. Galantamine was found to be a potent inhibitor of acetylcholinesterase and more effective than rivastigmine and donepezil. A controversial herbal supplement, Ginkgo Biloba, was examined to determine its relevance in reducing the severity of Alzheimer’s. Research findings support that the supplement's efficacy is inconclusive as trials have not been able to provide significant evidence as to whether or not Ginkgo Biloba is effective in the case of Alzheimer’s. By investigating the impact of prospective treatments on the mechanisms of Alzheimer’s, this extensive research aims to provide evidence to handle the effects of the disease and determine significant treatments to ensure the quality of healthcare for all patients distressed by Alzheimer’s Disease.
By: Vineel Gavini